Weis Holger 4

What Happened

• Holger Weis, CEO of Alaunos Therapeutics (TCRT), received an award/acquisition of 3,700 shares of common stock on May 22, 2026.
• The shares were issued at $2.37 per share for a total value of $8,769. This was a compensation issuance (award) rather than an open-market purchase or sale.

Key Details

• Transaction date and price: May 22, 2026 — 3,700 shares at $2.37 each.
• Total value: $8,769.
• Shares owned after transaction: not specified in the Form 4 filing.
• Footnote: F1 — shares were issued in lieu of net salary (compensation).
• Filing date: May 27, 2026. Because Form 4s are normally required within two business days of a reporting event, this filing appears to have been submitted after that window.

Context

• These shares were granted as compensation in lieu of cash salary, a common practice for executives; such awards reflect pay arrangements rather than an explicit purchase or sale decision in the market.
• This is an award (transaction code A) and does not necessarily indicate insider sentiment about the stock; purchases are typically more informative about an insider’s market view.